Our Pipeline

We are substantially investing in clinical activities and intellectual property management. Our clinical-stage first-in-class-candidate mocravimod is ready to enter the registration-enabling phase II/III studies. Mocravimod was tested positively in extensive Phase I studies, Phase 2a studies in autoimmune indications (Ulcerative Colitis, subacute cutaneous Lupus Erythematosus and Crohn’s Disease) and in a Phase 2a Hematopoietic Stem Cell Transplant (HSCT) study to treat hematological malignancies.

Contact Us

Priothera Ltd
88 Harcourt Street, Dublin 2, D02 DK18, Ireland

Priothera Ltd
88 Harcourt Street, Dublin 2,
D02 DK18, Ireland

Priothera SAS France
9 Rue du Temple, Saint Louis, 68300, France